Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01777269
Registration number
NCT01777269
Ethics application status
Date submitted
24/01/2013
Date registered
28/01/2013
Date last updated
20/08/2018
Titles & IDs
Public title
Prospective Sexual Function Study for BPH Subjects
Query!
Scientific title
A Prospective Study of Sexual Function in Sexually Active Men Treated for BPH
Query!
Secondary ID [1]
0
0
2012-002047-26
Query!
Secondary ID [2]
0
0
116115
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Prostatic Hyperplasia
0
0
Query!
Condition category
Condition code
Renal and Urogenital
0
0
0
0
Query!
Other renal and urogenital disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Dutasteride plus tamsulosin
Treatment: Drugs - Placebo
Experimental: Duodart - Fixed dose combination of dutasteride 0.5mg and tamsulosin 0.4mg. A capsule once daily during 12 months
Placebo Comparator: Sugar Pill - A capsule once daily during 12 months
Treatment: Drugs: Dutasteride plus tamsulosin
Take 1 capsule daily
Treatment: Drugs: Placebo
Take one capsule daily
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Changes From Baseline (BL) in Total Score From the Full Men's Sexual Health Questionnaire (MSHQ) at 12 Months
Query!
Assessment method [1]
0
0
Total MSHQ score is composed of 3 domain scores: Erection score(ES)=sum of score for Questions (Q) 1 to 3(ranges from 0 to 15), Ejaculation score(EjS)=sum of scores for Q5 to 11(ranges from 1 to 35), Satisfaction score(SS)=sum of scores for Q13 to 18(ranges from 6 to 30). Total MSHQ score=ES+EjS+SS. The total MSHQ score ranges from 7-80, with higher scores indicating greater sexual function. Change from BL at scheduled post-BL time points were analyzed using a mixed model repeated measures (MMRM) analysis method with an Observed Cases approach. Values are expressed as adjusted mean along with standard error. The MMRM analysis included fixed categorical effects of treatment, visit and treatment by visit interaction and the continuous fixed covariates of BL total score and BL score by visit interaction. BL is defined as earliest double-blind (DB) treatment start date if the par. took at least one dose of DB study drug; change from BL was calculated as Month 12 value(s) minus BL value(s)
Query!
Timepoint [1]
0
0
Baseline and 12 months
Query!
Secondary outcome [1]
0
0
Change From Baseline in Scores From the Full Men's Sexual Health Questionnaire (MSHQ) at 1, 3, 6 and 9 Months
Query!
Assessment method [1]
0
0
Total MSHQ score is composed of 3 domain scores: ES=sum of score for Q 1 to 3(ranges from 0 to 15), EjS=sum of scores for Q5 to 11(ranges from 1 to 35), SS=sum of scores for Q13 to 18(ranges from 6 to 30). Total MSHQ score=ES+EjS+SS and the score ranges from 7-80, with higher scores indicating greater sexual function. Change from BL at scheduled post-BL time points were analysed using MMRM analysis method with an Observed Cases approach. Values are expressed as adjusted mean along with standard error. The MMRM analysis included fixed categorical effects of treatment, visit and treatment by visit interaction and the continuous fixed covariates of BL total score and BL score by visit interaction. BL is defined as earliest DB treatment start date if the par. took at least one dose of DB study drug; change from BL was calculated as Month 1, 3, 6, 9 values minus BL value(s). Only those par with non-missing change from baseline data were analysed (presented as n=X,X in the category titles)
Query!
Timepoint [1]
0
0
Baseline and Month 1, 3, 6, and 9
Query!
Secondary outcome [2]
0
0
Number of Participants Reaching Various Thresholds of Change in Total MSHQ From Baseline at 12 Months
Query!
Assessment method [2]
0
0
Participants reaching thresholds of change in total MSHQ were assessed. Threshold values are defined as multiplicative factor. Threshold included +10 points, +20 points, +25 points, -10 points, -20 points, -25 points; where "+" indicates improvement and "-"indicates worsening. Treatment comparisons were done based on categories defined by these thresholds using Mantel-Haenszel test
Query!
Timepoint [2]
0
0
Baseline and 12 months
Query!
Secondary outcome [3]
0
0
Change From Baseline in Erectile Dysfunction (ED) at 1, 3, 6, 9 and 12 Months
Query!
Assessment method [3]
0
0
Erection scale is a domain of MSHQ to assess erectile dysfunction. ES is the sum of score for questions 1 to 3. The score ranges from 0 (no erection) to 15 (strong erection). Change from BL at the scheduled post-baseline time points were analyzed using MMRM analysis method with an Observed Cases approach. Values are expressed as adjusted mean along with standard error. The MMRM analysis included fixed categorical effects of treatment, visit and treatment by visit interaction and the continuous fixed covariates of BL total score and BL score by visit interaction. BL is defined as earliest DB treatment start date if the par. took at least one dose of DB study drug; change from BL was calculated as Month 1, 3, 6, 9 and 12 values minus BL value(s). Only those par with non-missing change from baseline data were analysed (presented as n=X,X in the category titles)
Query!
Timepoint [3]
0
0
Baseline and Month 1, 3, 6, 9 and 12
Query!
Secondary outcome [4]
0
0
Change From Baseline in Ejaculatory Dysfunction (EjD) at 1, 3, 6, 9 and 12 Months
Query!
Assessment method [4]
0
0
Ejaculation scale is a domain of MSHQ to assess ejaculatory dysfunction. EjS is the sum of score for questions 5 to 11. The score ranges from 1 (could not ejaculate) to 35 (strong ejaculation). Change from BL at the scheduled post-baseline time points were analyzed using MMRM analysis method with an Observed Cases approach. Values are expressed as adjusted mean along with standard error. The MMRM analysis included fixed categorical effects of treatment, visit and treatment by visit interaction and the continuous fixed covariates of BL total score and BL score by visit interaction. BL is defined as earliest DB treatment start date if the par. took at least one dose of DB study drug; change from BL was calculated as Month 1, 3, 6, 9 and 12 values minus BL value(s). Only those par with non-missing change from baseline data were analysed (presented as n=X,X in the category titles)
Query!
Timepoint [4]
0
0
Baseline and Month 1, 3, 6, 9 and 12
Query!
Secondary outcome [5]
0
0
Change From Baseline in Satisfaction Score at 1, 3, 6, 9 and 12 Months
Query!
Assessment method [5]
0
0
Satisfaction scale is a domain of MSHQ to assess sexual relationship. SS is the sum of score for questions 13 to 18. The score ranges from 6 (extremely dissatisfied) to 30 (extremely satisfied). Change from BL at the scheduled post-baseline time points were analyzed using MMRM analysis method with an Observed Cases approach. Values are expressed as adjusted mean along with standard error. The MMRM analysis included fixed categorical effects of treatment, visit and treatment by visit interaction and the continuous fixed covariates of BL total score and BL score by visit interaction. BL is defined as earliest DB treatment start date if the par. took at least one dose of DB study drug; change from BL was calculated as Month 1, 3, 6, 9 and 12 values minus BL value(s). Only those par with non-missing change from baseline data were analysed (presented as n=X,X in the category titles)
Query!
Timepoint [5]
0
0
Baseline and Month 1, 3, 6, 9 and 12
Query!
Secondary outcome [6]
0
0
Change From Baseline in International Prostate Symptom Score (IPSS) Scores Using the Observed Cases Approach at 2 Weeks, 1, 3, 6, 9, and 12 Months
Query!
Assessment method [6]
0
0
The IPSS questionnaire is a 7-item self-administered questionnaire designed to quantify urinary symptoms: Q1, incomplete emptying; Q2, frequency; Q3, intermittency; Q4, urgency; Q5, weak stream; Q6, straining; Q7, nocturia. The score can range from 0 to 35: mild (0 to 7), moderate (8 to 19), or severe (20 to 35). Change from BL were analyzed using MMRM analysis method with an Observed Cases approach. Values are expressed as adjusted mean along with standard error. The MMRM analysis included fixed categorical effects of treatment, visit and treatment by visit interaction and the continuous fixed covariates of BL total score and BL score by visit interaction. BL is defined as earliest DB treatment start date if the par. took at least one dose of DB study drug; change from BL was calculated as Week 2, Months 1, 3, 6, 9 and 12 values minus BL value(s). Only those par with non-missing change from baseline data were analysed (presented as n=X,X in the category titles)
Query!
Timepoint [6]
0
0
Baseline and Month 1, 3, 6, 9 and 12
Query!
Secondary outcome [7]
0
0
Change From Baseline in Quality of Life (BPH Impact Index -BII Scores) at 2 Weeks, 1, 3, 6, 9, and 12 Months
Query!
Assessment method [7]
0
0
The BPH Impact Index (BII) is a 4-item, self-administered questionnaire evaluating the impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. Change from BL were analyzed using MMRM analysis method with an Observed Cases approach. Values are expressed as adjusted mean along with standard error. The MMRM analysis included fixed categorical effects of treatment, visit and treatment by visit interaction and the continuous fixed covariates of BL total score and BL score by visit interaction. BL is defined as earliest DB treatment start date if the subject took at least one dose of DB study drug; change from BL was calculated as Week 2, Months 1, 3, 6, 9 and 12 values minus BL value(s). Only those par with non-missing change from baseline data were analysed (presented as n=X,X in the category titles)
Query!
Timepoint [7]
0
0
Baseline and Month 1, 3, 6, 9 and 12
Query!
Secondary outcome [8]
0
0
Change From Baseline in Perception of Treatment Benefit/Satisfaction With Treatment (Patient Perception of Study Medication - PPSM Questionnaire Scores) at 2 Weeks, 1, 3, 6, 9, and 12 Months
Query!
Assessment method [8]
0
0
Patient Perception of Study Medication (PPSM) is a 12-item questionnaire designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms. The total PPSM score ranges from 7 to 49, with higher scores indicating lower satisfaction. Change from BL were analyzed using MMRM analysis method with an Observed Cases approach. Values are expressed as adjusted mean along with standard error. The MMRM analysis included fixed categorical effects of treatment, visit and treatment by visit interaction and the continuous fixed covariates of BL total score and BL score by visit interaction. BL is defined as earliest DB treatment start date if the subject took at least one dose of DB study drug; change from BL was calculated as Week 2, Months 1, 3, 6, 9, 12 values minus BL value(s). Only those par with non-missing change from baseline data were analysed (presented as n=X,X in the category titles)
Query!
Timepoint [8]
0
0
Baseline, Week 2, Month 1, 3, 6, 9 and 12
Query!
Secondary outcome [9]
0
0
Change From Baseline in Total MSHQ Scores From Baseline at 12 Months Among Participants With IPSS Improvement of >=2 Points and >=3 Points
Query!
Assessment method [9]
0
0
Total MSHQ score is composed of 3 domain scores: ES+EjS+SS and the score ranges from 7-80, with higher scores indicating greater sexual function. Par. with change from baseline in total MSHQ scores with good BPH symptomatic response (measured by improvement in IPSS)were analysed. Change from BL at the scheduled post-baseline time points were analyzed using MMRM analysis method with an Observed Cases approach. Values are expressed as adjusted mean along with standard error. The MMRM analysis included fixed categorical effects of treatment, visit and treatment by visit interaction and the continuous fixed covariates of BL total score and BL score by visit interaction. BL is defined as earliest DB treatment start date if the par. took at least one dose of DB study drug; change from BL was calculated as Month 12 value(s) minus BL value(s). Only those par with non-missing change from baseline data were analysed (presented as n=X,X in the category titles)
Query!
Timepoint [9]
0
0
Baseline and Month 12
Query!
Secondary outcome [10]
0
0
Change From Baseline in Total MSHQ Scores From Baseline at 12 Months Among Participants With IPSS Improvement of >=25 Percent
Query!
Assessment method [10]
0
0
Participants with change from baseline in total MSHQ scores with good BPH symptomatic response (measured by improvement in IPSS)were analysed.Change from BL at the scheduled post-baseline time points were analyzed using MMRM analysis method with an Observed Cases approach. Values are expressed as adjusted mean along with standard error. The MMRM analysis included fixed categorical effects of treatment, visit and treatment by visit interaction and the continuous fixed covariates of BL total score and BL score by visit interaction. BL is defined as earliest DB treatment start date if the par. took at least one dose of DB study drug; change from BL was calculated as Month 12 value(s) minus BL value(s). Only those par with non-missing change from baseline data were analysed (presented as n=X,X in the category titles)
Query!
Timepoint [10]
0
0
Baseline and Month 12
Query!
Eligibility
Key inclusion criteria
- Males aged =50 years.
- Men must be sexually active. A man is considered sexually active if he has been
engaged in sexual activity with a partner during the past 4 weeks (at least once) and
plans to be active during the next 4 weeks (unless due to travel or other practical
reasons). Men should confirm that they are in a stable relationship and expect to
maintain their sexual activity over the next year.
- A confirmed clinical diagnosis of BPH.
- International Prostate Symptom Score (IPSS) =12 at Visit 1 (screening), with bother
score 4 or less (score from the IPSS Quality of Life question 8).
- Prostate volume =30 cc (by transrectal ultrasonography; TRUS). Measurement should be
available by the baseline visit and should have been made /arranged at the screening
visit or within the previous 6 months.
- Total serum prostate specific antigen (PSA =1.5 ng/mL (see exclusion criteria 1) at
Visit 1 (screening).
- Willing and able to give signed written informed consent and comply with study
procedures, including the ability to participate in the study for the full 1 year (or
18 months if necessary because of a persistent sexual AE).
- Fluent and literate in local language with the ability to read, comprehend and record
information on the MSHQ, IPSS, PPSM, BPH Impact Index (BII) and C-SSRS questionnaires.
- Able to swallow and retain oral medication.
- Men with a female partner of childbearing potential must either agree to use effective
contraception or have had a prior vasectomy. Contraception must be used from 2 weeks
prior to administration of the first dose of study treatment until at least 5
half-lives for the drug (45 days) plus 3 months (i.e. a total of 4.5 months) to allow
clearance of any altered sperm after the last dose of study treatment.
- French subjects: In France, a subject will be eligible for inclusion in this study
only if either affiliated to or a beneficiary of a social security category.
Query!
Minimum age
50
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Total serum PSA >10.0 ng/mL at Visit 1 (screening).
- History or evidence of prostate cancer (e.g. positive biopsy or ultrasound, suspicious
DRE and/or rising PSA). Subjects with suspicious ultrasound or DRE who have had a
negative biopsy within the preceding 6 months and stable PSA are eligible for the
study.
Note: If total serum PSA is >4ng/mL and unless PSA value has been stable for at least the
past 2 years, the investigator should make every appropriate effort to exclude the
possibility of prostate cancer, including consideration of prostate biopsy.
Excluded medication and therapies
- Current or prior use (within the periods given) of the following prohibited
medications
- Any prior use of a 5a-reductase inhibitor (finasteride or dutasteride),
- Anti-cholinergics (e.g. oxybutynin, propantheline, tolerodine, solifenacin or
darifenacin) within 1 month prior to visit 2 (baseline)
- An alpha-adrenoreceptor blocker (i.e. indoramin, prazosin, terazosin, tamsulosin,
alfuzosin and doxazosin) within 1 month prior to visit 2 (baseline)
- Use of any drugs with anti-androgenic properties (e.g. spironolactone, flutamide,
bicalutamide, cimetidine, ketoconazole, progestational agents) within the 6 months
prior to visit 1 (screening).
- Use of any drugs noted for propensity to cause gynaecomastia, or which could affect
prostate volume, within 6 months prior to Visit 1 (screening).
- Use of any investigational or marketed study drug within 30 days or 5 half-lives of
the drug in question, (whichever is longer), preceding visit 2 (baseline).
- Current use (at the baseline visit or within the prior 1month) of:
- PDE-5 inhibitors for Erectile Dysfunction.
- Anabolic steroids.
- Drugs known or thought to have an interaction with tamsulosin, e.g. cimetidine and
warfarin.
- Use of phytotherapy for BPH within 2 weeks prior to Visit 1 (screening) and/or
predicted to need phytotherapy during the study.
- History of a known (immediate or delayed) hypersensitivity reaction or idiosyncratic
reaction to drugs chemically related to the study medication or excipients that, in
the opinion of the Investigator or GSK, contraindicate their participation.
- Previous prostatic surgery (including TURP, balloon dilatation, thermotherapy and
stent replacement) or other invasive or minimally invasive procedures to treat BPH.
Recent Medical Procedures
- History of flexible/rigid cystoscopy or other instrumentation of the urethra within 7
days prior to Visit 1 (screening). Catheterisation (<10F) is acceptable with no time
restriction.
Medical history
- Presence of structural abnormalities in the Lower Urinary Tract or sexual organs (e.g.
urethral stricture, Peyronie's Disease etc) that may cause LUTS or sexual dysfunction.
- History of AUR.
- Post-void residual volume >100 mL (suprapubic ultrasound) at Visit 1 (screening) or a
recorded PVR above this level on any previous examination. Measurement should be
available by the baseline visit and should have been made /arranged at the screening
visit or within the previous 6 months.
- Any causes other than BPH, which may in the judgement of the investigator, result in
urinary symptoms (e.g. neurogenic bladder, bladder neck contracture, urethral
stricture, bladder malignancy, acute or chronic prostatitis, or acute or chronic
urinary tract infections).
- History of 'first dose' hypotensive episode on initiation of alpha-1-adrenoreceptor
antagonist therapy.
- History of postural hypotension, dizziness, vertigo or any other signs and symptoms of
orthostasis, which in the opinion of the investigator could be exacerbated by
tamsulosin and result in putting the subject at risk of injury.
- History of breast cancer or clinical breast examination finding of unclear origin or
suggestive of malignancy.
- Prior history of malignancies (other than basal cell carcinoma or squamous cell
carcinoma of the skin) within the past 5 years. Subjects with an earlier history of
malignancy who have had no evidence of disease for at least the past 5 years are
eligible.
- History of hepatic impairment or abnormal liver function tests at Visit 1 (screening)
(defined as ALT, AST or alkaline phosphatase >2 times the ULN, or total bilirubin >1.5
times the ULN (unless associated with predominantly indirect bilirubin elevation or
Gilbert's syndrome).
- History of renal insufficiency, or serum creatinine >1.5 times the upper limit of
normal at Visit 1 (screening).
- Any unstable, serious co-existing medical condition(s) including, but not limited to,
myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias,
clinically evident congestive heart failure, or cerebrovascular accident within 6
months prior to the Screening visit; uncontrolled diabetes or peptic ulcer disease
which is uncontrolled by medical management.
- History or current evidence of drug or alcohol abuse within the previous 12 months.
- History or presence of any serious and/or unstable pre-existing psychiatric disorder
or other conditions that in the opinion of the Investigator or GSK Medical Monitor,
could interfere with subject's safety, obtaining informed consent, compliance to the
study procedures, or confound the results of the study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
18/02/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
5/04/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
489
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Randwick
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Sydney
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Wahroonga
Query!
Recruitment hospital [4]
0
0
GSK Investigational Site - Herston
Query!
Recruitment hospital [5]
0
0
GSK Investigational Site - Kippa-Ring
Query!
Recruitment hospital [6]
0
0
GSK Investigational Site - Adelaide
Query!
Recruitment hospital [7]
0
0
GSK Investigational Site - Heidelberg
Query!
Recruitment hospital [8]
0
0
GSK Investigational Site - Malvern
Query!
Recruitment postcode(s) [1]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [2]
0
0
2000 - Sydney
Query!
Recruitment postcode(s) [3]
0
0
2076 - Wahroonga
Query!
Recruitment postcode(s) [4]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [5]
0
0
4021 - Kippa-Ring
Query!
Recruitment postcode(s) [6]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [7]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [8]
0
0
3144 - Malvern
Query!
Recruitment outside Australia
Country [1]
0
0
France
Query!
State/province [1]
0
0
Garches
Query!
Country [2]
0
0
France
Query!
State/province [2]
0
0
Nantes cedex 2
Query!
Country [3]
0
0
France
Query!
State/province [3]
0
0
Nîmes cedex 9
Query!
Country [4]
0
0
France
Query!
State/province [4]
0
0
Orleans
Query!
Country [5]
0
0
France
Query!
State/province [5]
0
0
Paris Cedex 13
Query!
Country [6]
0
0
France
Query!
State/province [6]
0
0
Thouars
Query!
Country [7]
0
0
Germany
Query!
State/province [7]
0
0
Bayern
Query!
Country [8]
0
0
Germany
Query!
State/province [8]
0
0
Brandenburg
Query!
Country [9]
0
0
Germany
Query!
State/province [9]
0
0
Hessen
Query!
Country [10]
0
0
Germany
Query!
State/province [10]
0
0
Niedersachsen
Query!
Country [11]
0
0
Germany
Query!
State/province [11]
0
0
Nordrhein-Westfalen
Query!
Country [12]
0
0
Germany
Query!
State/province [12]
0
0
Sachsen-Anhalt
Query!
Country [13]
0
0
Germany
Query!
State/province [13]
0
0
Sachsen
Query!
Country [14]
0
0
Germany
Query!
State/province [14]
0
0
Schleswig-Holstein
Query!
Country [15]
0
0
Germany
Query!
State/province [15]
0
0
Berlin
Query!
Country [16]
0
0
Germany
Query!
State/province [16]
0
0
Eisleben
Query!
Country [17]
0
0
Greece
Query!
State/province [17]
0
0
Argos
Query!
Country [18]
0
0
Greece
Query!
State/province [18]
0
0
Athens
Query!
Country [19]
0
0
Greece
Query!
State/province [19]
0
0
Larisa
Query!
Country [20]
0
0
Hungary
Query!
State/province [20]
0
0
Budapest
Query!
Country [21]
0
0
Hungary
Query!
State/province [21]
0
0
Debrecen
Query!
Country [22]
0
0
Hungary
Query!
State/province [22]
0
0
Miskolc
Query!
Country [23]
0
0
Hungary
Query!
State/province [23]
0
0
Nyíregyháza
Query!
Country [24]
0
0
Hungary
Query!
State/province [24]
0
0
Szentes
Query!
Country [25]
0
0
Netherlands
Query!
State/province [25]
0
0
Almere
Query!
Country [26]
0
0
Netherlands
Query!
State/province [26]
0
0
Beek
Query!
Country [27]
0
0
Netherlands
Query!
State/province [27]
0
0
Doetinchem
Query!
Country [28]
0
0
Netherlands
Query!
State/province [28]
0
0
EDE
Query!
Country [29]
0
0
Netherlands
Query!
State/province [29]
0
0
Eindhoven
Query!
Country [30]
0
0
Netherlands
Query!
State/province [30]
0
0
Sneek
Query!
Country [31]
0
0
Netherlands
Query!
State/province [31]
0
0
Utrecht
Query!
Country [32]
0
0
Netherlands
Query!
State/province [32]
0
0
Winterswijk
Query!
Country [33]
0
0
Spain
Query!
State/province [33]
0
0
Alcazar De San Juan (Ciudad Real)
Query!
Country [34]
0
0
Spain
Query!
State/province [34]
0
0
Barcelona
Query!
Country [35]
0
0
Spain
Query!
State/province [35]
0
0
Bormujo (Sevilla)
Query!
Country [36]
0
0
Spain
Query!
State/province [36]
0
0
Cadiz
Query!
Country [37]
0
0
Spain
Query!
State/province [37]
0
0
Coslada
Query!
Country [38]
0
0
Spain
Query!
State/province [38]
0
0
Getafe/Madrid
Query!
Country [39]
0
0
Spain
Query!
State/province [39]
0
0
Granada
Query!
Country [40]
0
0
Spain
Query!
State/province [40]
0
0
Guadalajara
Query!
Country [41]
0
0
Spain
Query!
State/province [41]
0
0
Madrid
Query!
Country [42]
0
0
Spain
Query!
State/province [42]
0
0
Marbella
Query!
Country [43]
0
0
Spain
Query!
State/province [43]
0
0
Mendaro, Guipuzcoa
Query!
Country [44]
0
0
Spain
Query!
State/province [44]
0
0
Murcia
Query!
Country [45]
0
0
Spain
Query!
State/province [45]
0
0
Toledo
Query!
Country [46]
0
0
Spain
Query!
State/province [46]
0
0
Vitoria- Gasteiz
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is an European double-blind, placebo controlled parallel group comparison of DUODART
(fixed dose combination of dutasteride 0.5mg and tamsulosin 0.4mg, one capsule daily) and
placebo.
PRIMARY OBJECTIVE:
To assess the change in sexual function from baseline to 1 year in sexually active men with
at least moderate BPH who are treated with DUODART, compared to men treated with placebo .
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01777269
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01777269
Download to PDF